Relapse prevention (RP) plays a major role in the vast number of treatment programs for sexual offenders. However, despite its widespread application, questions have been raised regarding the uncritical adoption of the approach (R. K. Hanson, 1996). More specifically, the way in which it is presented to sexual offenders has been criticized for being unhelpfully negative in focus (Mann, 2000) and it has been suggested that treatment should adopt a broader focus on improving quality of life (T. Ward and C. A. Stewart, 2003), with the expectation that recidivism would reduce as a side-effect. The current study evaluated two orientations to relapse prevention, comparing a deliberately positively-focused orientation, focusing on creating a "good life," to the more traditional approach that focuses on avoiding and controlling risk factors. Twenty-four participants completed an approach-focused RP intervention and 23 completed an avoidance-focused RP intervention. Results indicated that participants who completed the approach-focused intervention had a greater engagement in treatment as measured by homework compliance and willingness to disclose lapses. Furthermore, participants within the approach-focused intervention were rated by therapist to be more genuinely motivated to live life without offending by the end of treatment. However, differences between the groups in terms of self-esteem change following treatment were not very marked. These results are discussed in terms of their implications for treatment delivery.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/107906320401600105 | DOI Listing |
Recent breakthrough findings in clinical trials on amyloid-lowering therapies have led to the approval of these drugs for the treatment of amyloid- positive elderly individuals who show symptoms of mild cognitive impairment and mild dementia. The next frontier is the testing the efficacy of treatments for secondary prevention of AD dementia. Phase III trials in asymptomatic AD are already under way, raising a host of novel questions on the sequelae of trial participation such as the emotional and social repercussions of biomarker disclosure, understanding the risk of side effects and eventually weighing the risk-benefit ratio of amyloid-lowering treatment.
View Article and Find Full Text PDFBackground: A new era of Alzheimer's disease (AD) research is beginning now that multiple monoclonal antibodies (mABs) are on the market. Their use may not be widespread initially but will be more common in clinical sites likely to participate in clinical trials and will continue to grow. Many AD investigational treatments have been studied as add-on to acetylcholinesterase inhibitors; however, putative disease-modifying therapies (DMTs) like mABs are expected to alter the underlying rate of progression, potentially reducing our ability to detect effects of other DMTs on top of mABs.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
National Hospital for Neurology and Neurosurgery, University College London, London, London, United Kingdom.
Anti-amyloid therapies are ideal candidates for prevention trials. Secondary prevention in those at risk of ADAD (DIAN-TU) has shown reduction of brain amyloid deposition leads to significant downstream biological change; early secondary prevention using a monoclonal antibody in sporadic AD (AHEAD 3-45) is ongoing and will provide critical information on whether treating earlier leads to greater clinical benefit. However, this is not preventing disease but delaying onset in those with presymptomatic disease.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Chungnam National University, College of Nursing, Daejeon, Korea, Republic of (South).
Background: The aging population in rural areas is a unique health challenge. Older adults with cognitive decline are particularly vulnerable due to limited access to medical resources and health-related information, a disparity more pronounced in rural compared to urban settings. This study investigates key factors influencing perceived decision-making competence for health behavior in this demographic.
View Article and Find Full Text PDFMol Cancer Ther
January 2025
Albert Einstein College of Medicine, Bronx, NY, United States.
Osteosarcoma (OS) is the most common primary malignant bone tumor in childhood. Patients who present with metastatic disease at diagnosis or relapse have a very poor prognosis, and this has not changed over the past four decades. The Wnt signaling pathway plays a role in regulating osteogenesis and is implicated in OS pathogenesis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!